425: Kintara Therapeutics and TuHURA Biosciences Announce Corporate and Clinical Updates, Outline Near-Term Milestones

Kintara Therapeutics and TuHURA Biosciences provide an update on their recent corporate and clinical advancements, including the planned merger and clinical trial progress, and outline expected near-term milestones.

Summary

• Kintara Therapeutics and TuHURA Biosciences have provided an update on their recent corporate and clinical advancements.
• The companies entered into a definitive merger agreement in April 2024, with the merger expected to close in the third quarter of 2024.
• Kintara's existing stockholders will own approximately 5.5% of the combined company's common stock at closing, including a contingent value right (CVR) linked to REM-001 study enrollment.
• TuHURA plans to advance a Phase 3 trial for IFx-2.0 personalized cancer vaccine in the second half of 2024.
• TuHURA has secured $31 million in subscribed financing in connection with the Merger Agreement, expected to provide cash runway into late 2025.
• Kintara received a 180-day extension until December 9, 2024, to regain compliance with Nasdaq's minimum bid price requirement.
• Enrollment, dosing, and clinical site expansion are advancing in Kintara's open-label 15-patient REM-001 study in cutaneous metastatic breast cancer (CMBC).
• As of June 26, 2024, four patients have been dosed in the REM-001 study.
• Kintara expanded inclusion criteria in the REM-001 study in March 2024 to include patients receiving pembrolizumab (KEYTRUDA) for at least three months at screening, which is expected to increase enrollment pace.
• Kintara expects to complete enrollment and an 8-week follow-up of 10 patients in the REM-001 study by the fourth calendar quarter of 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the merger progress, secured financing, and clinical trial advancements. However, concerns about dilution and Nasdaq compliance temper the overall outlook.

Positives

• TuHURA's $31 million financing provides a cash runway into late 2025, ensuring operational stability.
• The expansion of inclusion criteria in the REM-001 study is expected to accelerate patient enrollment.
• The REM-001 study is largely funded by a $2.0 million SBIR grant from the NIH.
• TuHURA's first-in-class bifunctional Antibody Drug Conjugates (ADCs) represent potential upside partnering opportunities.

Negatives

• Kintara's existing stockholders will own only approximately 5.5% of the combined company after the merger, which may dilute their ownership significantly.
• Kintara needed an extension from Nasdaq to regain compliance with the minimum bid price requirement, indicating potential financial challenges.

Risks

• The merger is subject to various risks, including failure to obtain stockholder approval and uncertainties regarding the timing of consummation.
• Delays in closing the merger could impact the anticipated cash resources of the combined company.
• Legal proceedings related to the merger could arise, causing unexpected costs and delays.
• The combined business may not be successful, and competitive responses to the merger could negatively impact the company.
• Kintara and TuHURA may face challenges in protecting their respective intellectual property rights.

Future Outlook

The combined company will focus on advancing TuHURA's IFx-2.0 personalized cancer vaccine and Kintara's REM-001 therapy, with key milestones including the commencement of a Phase 3 trial for IFx-2.0 and completion of enrollment in the REM-001 study.

Industry Context

The merger reflects a trend in the biopharmaceutical industry towards consolidation and strategic partnerships to enhance pipelines and secure funding. TuHURA's focus on overcoming resistance to cancer immunotherapy aligns with the growing interest in personalized cancer vaccines and ADCs.

Comparison to Industry Standards

• TuHURA's IFx-2.0 personalized cancer vaccine is comparable to other companies developing personalized cancer vaccines, such as BioNTech and Moderna, though it targets a different mechanism of action.
• The $31 million subscribed financing is relatively small compared to larger financings in the biotech industry, but it is significant for a company of TuHURA's size and stage of development.
• Kintara's REM-001 therapy is similar to other photodynamic therapies being developed for localized cancer treatment, such as those by Photocure and Theralase Technologies.

Stakeholder Impact

• Shareholders of Kintara will experience dilution due to the merger, but may benefit from the combined company's potential.
• Employees of both companies face uncertainty during the merger process, but may gain new opportunities in the combined entity.
• Patients may benefit from the advancement of new cancer therapies.

Next Steps

• Close the merger with TuHURA in Q3 2024.
• Complete enrollment and 8-week follow-up of 10 patients in the REM-001 study by Q4 2024.
• Commence TuHURA's Phase 3 trial for IFx-2.0 in the second half of 2024.

Key Dates